fashion -WSS

fashion

author：entertainment 2025-09-29 19:05:03 - browse：87

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

leisure time

WSS

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

How many hemophilia patients actually want gene therapy?

Change Healthcare outage fallout shows need for new oversight

Xenotransplantation trials will require adjusting expectations, experts say

Mom launches Girl Scout troop for LGBTQ youth in Texas

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Wikipedia

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

New air purifier tech could be key to improving indoor air quality

How to save health care price transparency rules

The high cost of giving birth even with insurance

How to fix the rural physician shortage in the U.S.

Heart attack and stroke risk calculators need revising

Altering the blood type of lungs raises potential for universal organs for transplants

In Memoriam: Notable people who died in 2023

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Medicare proposal to cover medical devices draws a mixed reaction

How many hemophilia patients actually want gene therapy?

focus

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Eli Lilly’s Mounjaro succeeds in second weight

EPA limits use of carcinogenic gas for sterilizing medical devices

Novo pauses ads for weight loss drug Wegovy amid demand

John Green on his newest strategy for fighting tuberculosis

Xenotransplantation trials will require adjusting expectations, experts say

leisure time

hotspot

focus

explore